The pharmaceutical company AI-Therapeutics (Guilford, CT, USA) has acquired the preclinical drug candidates EC-8042 and EC-70124 in the course of the insolvency proceedings EntreChem was experiencing since February of last... read more →
EntreChem has entered a development agreement with Instituto Biomar SA (León, Spain) to exploit EntreChem proprietary technology regarding the use of combinatorial biosynthesis and biotransformations for the generation of molecular... read more →
EntreChem has entered a collaborative agreement with Laboratoires Servier (Paris, France) to exploit EntreChem proprietary technology regarding the use of combinatorial biosynthesis and biotransformations for the generation of molecular diversity... read more →
EntreChem has signed an agreement with Genoma España, and it has been incorporated to Genoma’s Technology Portfolio. The agreement supports the creation of the company as well as represents an... read more →